An update on the pharmacological treatment of generalized anxiety disorder

Detalhes bibliográficos
Autor(a) principal: Mochcovitch, Marina Dyskant
Data de Publicação: 2015
Tipo de documento: Artigo
Idioma: por
Título da fonte: Debates em Psiquiatria (Online)
Texto Completo: https://revistardp.org.br/revista/article/view/206
Resumo: Generalized anxiety disorder (GAD) is a chronic and prevalent disorder, but also one of the least studied among anxiety disorders. Selective serotonin reuptake inhibitors (SSRI) and selective norepinephrine reuptake inhibitors (SNRI) are considered first-line drugs in the treatment of GAD, but refractory cases and the occurrence of intolerance and contraindications to these drugs are not uncommon. In this scenario, various substances, e.g., pregabalin and quetiapine, have emerged as alternatives for the treatment of TAG in these patients, as well as for replacing the use of benzodiazepines as adjunctive therapy to antidepressants.
id ABP-2_24378dd96aaae4d57fc900ff77948bbf
oai_identifier_str oai:ojs.emnuvens.com.br:article/206
network_acronym_str ABP-2
network_name_str Debates em Psiquiatria (Online)
repository_id_str
spelling An update on the pharmacological treatment of generalized anxiety disorderAtualizações do tratamento farmacológico do transtorno de ansiedade generalizada Transtorno de ansiedade generalizadatratamentoensaios clínicosGeneralized anxiety disordertreatmentclinical trialsGeneralized anxiety disorder (GAD) is a chronic and prevalent disorder, but also one of the least studied among anxiety disorders. Selective serotonin reuptake inhibitors (SSRI) and selective norepinephrine reuptake inhibitors (SNRI) are considered first-line drugs in the treatment of GAD, but refractory cases and the occurrence of intolerance and contraindications to these drugs are not uncommon. In this scenario, various substances, e.g., pregabalin and quetiapine, have emerged as alternatives for the treatment of TAG in these patients, as well as for replacing the use of benzodiazepines as adjunctive therapy to antidepressants.O transtorno de ansiedade generalizada (TAG) é um transtorno crônico e prevalente, mas também um dos menos estudados entre os transtornos de ansiedade. Os antidepressivos inibidores seletivos da recaptação da serotonina (ISRS) e inibidores da recaptação da serotonina e noradrenalina (IRSN) são considerados medicamentos de primeira linha no tratamento de TAG, porém não são incomuns casos de refratariedade, intolerância ou a presença de contraindicações ao uso dessas subtâncias. Diversas substâncias, como a pregabalina e a quetiapina, surgem, então, como alternativas para o tratamento do TAG nesses casos, assim como para a substituição dos benzodiazepínicos como medicações adjuvantes aos antidepressivos.Associação Brasileira de Psiquiatria2015-04-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-ReviewedRevisado por ParesAvaliado Pelos Paresapplication/pdfhttps://revistardp.org.br/revista/article/view/20610.25118/2236-918X-5-2-3Debates in Psychiatry; Vol. 5 No. 2 (2015); 14-18Debates em Psiquiatria; Vol. 5 Núm. 2 (2015); 14-18Debates em Psiquiatria; v. 5 n. 2 (2015); 14-182763-90372236-918Xreponame:Debates em Psiquiatria (Online)instname:Associação Brasileira de Psiquiatria (ABP)instacron:ABPporhttps://revistardp.org.br/revista/article/view/206/179https://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessMochcovitch, Marina Dyskant2023-06-07T17:43:05Zoai:ojs.emnuvens.com.br:article/206Revistahttps://revistardp.org.br/revista/oaiPUBhttps://revistardp.org.br/revista/oairdp@abp.org.br2763-90372236-918Xopendoar:2023-06-07T17:43:05Debates em Psiquiatria (Online) - Associação Brasileira de Psiquiatria (ABP)false
dc.title.none.fl_str_mv An update on the pharmacological treatment of generalized anxiety disorder
Atualizações do tratamento farmacológico do transtorno de ansiedade generalizada
title An update on the pharmacological treatment of generalized anxiety disorder
spellingShingle An update on the pharmacological treatment of generalized anxiety disorder
Mochcovitch, Marina Dyskant
Transtorno de ansiedade generalizada
tratamento
ensaios clínicos
Generalized anxiety disorder
treatment
clinical trials
title_short An update on the pharmacological treatment of generalized anxiety disorder
title_full An update on the pharmacological treatment of generalized anxiety disorder
title_fullStr An update on the pharmacological treatment of generalized anxiety disorder
title_full_unstemmed An update on the pharmacological treatment of generalized anxiety disorder
title_sort An update on the pharmacological treatment of generalized anxiety disorder
author Mochcovitch, Marina Dyskant
author_facet Mochcovitch, Marina Dyskant
author_role author
dc.contributor.author.fl_str_mv Mochcovitch, Marina Dyskant
dc.subject.por.fl_str_mv Transtorno de ansiedade generalizada
tratamento
ensaios clínicos
Generalized anxiety disorder
treatment
clinical trials
topic Transtorno de ansiedade generalizada
tratamento
ensaios clínicos
Generalized anxiety disorder
treatment
clinical trials
description Generalized anxiety disorder (GAD) is a chronic and prevalent disorder, but also one of the least studied among anxiety disorders. Selective serotonin reuptake inhibitors (SSRI) and selective norepinephrine reuptake inhibitors (SNRI) are considered first-line drugs in the treatment of GAD, but refractory cases and the occurrence of intolerance and contraindications to these drugs are not uncommon. In this scenario, various substances, e.g., pregabalin and quetiapine, have emerged as alternatives for the treatment of TAG in these patients, as well as for replacing the use of benzodiazepines as adjunctive therapy to antidepressants.
publishDate 2015
dc.date.none.fl_str_mv 2015-04-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-Reviewed
Revisado por Pares
Avaliado Pelos Pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revistardp.org.br/revista/article/view/206
10.25118/2236-918X-5-2-3
url https://revistardp.org.br/revista/article/view/206
identifier_str_mv 10.25118/2236-918X-5-2-3
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revistardp.org.br/revista/article/view/206/179
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Associação Brasileira de Psiquiatria
publisher.none.fl_str_mv Associação Brasileira de Psiquiatria
dc.source.none.fl_str_mv Debates in Psychiatry; Vol. 5 No. 2 (2015); 14-18
Debates em Psiquiatria; Vol. 5 Núm. 2 (2015); 14-18
Debates em Psiquiatria; v. 5 n. 2 (2015); 14-18
2763-9037
2236-918X
reponame:Debates em Psiquiatria (Online)
instname:Associação Brasileira de Psiquiatria (ABP)
instacron:ABP
instname_str Associação Brasileira de Psiquiatria (ABP)
instacron_str ABP
institution ABP
reponame_str Debates em Psiquiatria (Online)
collection Debates em Psiquiatria (Online)
repository.name.fl_str_mv Debates em Psiquiatria (Online) - Associação Brasileira de Psiquiatria (ABP)
repository.mail.fl_str_mv rdp@abp.org.br
_version_ 1796798364839313408

Registros relacionados